The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for tamponade hemostasis of bone or cartilage.

The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for tamponade hemostasis of bone or cartilage.

An ostomy appliance has a waste collection bag attached to an adhesive wafer. The adhesive wafer includes an adhesive layer, a backing layer deposited on a distal side of the adhesive layer, a hole formed through the adhesive layer, and a neutralizing layer deposited on the distal side of the adhesive layer. The neutralizing layer is in direct contact with the adhesive layer and is inside of the waste collection bag. The neutralizing layer has a neutralizer that is adapted to neutralize output from the stoma.

An ostomy appliance has a waste collection bag attached to an adhesive wafer. The adhesive wafer includes an adhesive layer, a backing layer deposited on a distal side of the adhesive layer, a hole formed through the adhesive layer, and a neutralizing layer deposited on the distal side of the adhesive layer. The neutralizing layer is in direct contact with the adhesive layer and is inside of the waste collection bag. The neutralizing layer has a neutralizer that is adapted to neutralize output from the stoma.

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty acid anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

Disclosed herein is a polymer composition comprising an effective amount of a hydrophobically-modified polymer having functional groups along the backbone occupied by a fatty acid anhydride moiety. The polymer composition has a potent hemostatic action by gelling blood upon contact, and is suitable for treating internal and external bleeds. As disclosed herein, the modified polymer can be generated without the use of toxic reagents that would require removal from the product. Further, compositions are shelf stable even in a flowable form. That is, the hydrophobic grafts are not lost under product storage conditions (e.g., room temperature storage).

The present invention relates to a shear-activated nanotherapeutic (SA-NT) for use in treating stroke by increasing blood supply to the brain via collateral vessels, wherein the SA-NT comprises an aggregate comprising a plurality of nanoparticles, the aggregate further comprising one or more vasodilating agents or pharmaceutically acceptable salts thereof; wherein the aggregate is configured to disaggregate above a predetermined shear stress.

An adhesive sheet includes cyclodextrin and a derivative polymer in which an alkyl group having a carbon number of 6 to 18 is introduced into a hydrophilic polymer, and at least a part of the alkyl group is in the form of inclusion with the cyclodextrin.

In some aspects, the present disclosure pertains to injectable polysaccharide-based hydrogels that comprises an anionic polysaccharide, a cationic crosslinking agent and a hemostatic agent. In some aspects, the present disclosure pertains to medical devices containing such injectable polysaccharide-based hydrogels, to kits that contain such injectable polysaccharide-based hydrogels, and to methods of using such injectable polysaccharide-based hydrogels.

In some aspects, the present disclosure pertains to injectable polysaccharide-based hydrogels that comprises an anionic polysaccharide, a cationic crosslinking agent and a hemostatic agent. In some aspects, the present disclosure pertains to medical devices containing such injectable polysaccharide-based hydrogels, to kits that contain such injectable polysaccharide-based hydrogels, and to methods of using such injectable polysaccharide-based hydrogels.